RBCC Joint Venture Partner n3D to Present Latest 3D Bioprinting Research in Washington, D.C.

MIRAMAR BEACH, Fla.--()--Rainbow Coral Corp.’s (OTCBB:RBCC) 3D bioprinting joint venture partner Nano3D Biosciences (n3D) will present a new abstract detailing the latest breakthroughs made using its technology in Washington, D.C. on Wednesday at the 4th annual Society for Laboratory Automation and Screening Conference and Exhibition (SLAS2015).

At the exhibition, n3D president Glauco R. Souza will help to present an abstract he co-wrote titled “High-throughput sheroid printing and toxicity testing using magnetic 3D bioprinting.” The presentation will explore some of the joint venture’s most recent and exciting results demonstrating the ability of its magnetic 3D bioprinting technology to create spheroid cell cultures rapidly and reproducibly for high-throughput and high-content compound screening.

“It’s a testament to the breakthrough potential of this technology that n3D has been invited to present at such a prestigious event,” said RBCC CEO Kimberly Palmer. “This is the perfect opportunity to demonstrate the enormous potential of 3D bioprinting in front of a crowd of people devoted to automated lab screening. We expect to make many new important contacts in Washington.”

For months, RBCC and n3D have been focused on raising product awareness to further market and develop the Bio-Assembler and other 3D bioprinting technology around the globe. The device uses biocompatible magnetic nanoparticles to magnetically bioprint and levitate cells, allowing them to grow into 3D structures much faster and more simply than competing technologies.

Through its biotech subsidiary, Rainbow Biosciences, RBCC markets and develops new medical and research technology innovations to compete alongside companies such as Biogen Idec Inc. (NASDAQ: BIIB), Abbott Laboratories (NYSE: ABT) and Amgen Inc. (NASDAQ: AMGN). Rainbow Biosciences acquired an equity interest in n3D in 2012.

About Rainbow Biosciences

Rainbow Biosciences, LLC, is a wholly owned subsidiary of Rainbow Coral Corp. (OTCBB:RBCC). The Company continually seeks out new partnerships with biotechnology developers to deliver profitable new medical technologies and innovations. For more information on our growth-oriented business initiatives, please visit www.RainbowBioSciences.com. For investment information and performance data on the Company, please visit www.RainbowBioSciences.com/investors.html.

Notice Regarding Forward-Looking Statements

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This news release contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements that include the words "believes," "expects," "anticipate" or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company to differ materially from those expressed or implied by such forward-looking statements. In addition, description of anyone's past success, either financial or strategic, is no guarantee of future success. This news release speaks as of the date first set forth above and the Company assumes no responsibility to update the information included herein for events occurring after the date hereof.

Contacts

Rainbow Coral Corp.
Kimberly Palmer, 850-269-7230
President and CEO
info@rainbowcoral.com

Release Summary

RBCC partner n3D Biosciences presents new 3D bioprinting technology in Washington, D.C.

Contacts

Rainbow Coral Corp.
Kimberly Palmer, 850-269-7230
President and CEO
info@rainbowcoral.com